CN Patent

CN112266384A — ErbB受体抑制剂

Assigned to Dizhe Jiangsu Pharmaceutical Co ltd · Expires 2021-01-26 · 5y expired

What this patent protects

本申请公开了ErbB受体抑制剂，即抑制ErbB(例如HER2)的化合物，其药学上可接受的盐，以及包含所述化合物的药物组合物。所述化合物和所述药物组合物可以有效地治疗ErbB(特别是HER2)相关疾病，包括癌症。

USPTO Abstract

本申请公开了ErbB受体抑制剂，即抑制ErbB(例如HER2)的化合物，其药学上可接受的盐，以及包含所述化合物的药物组合物。所述化合物和所述药物组合物可以有效地治疗ErbB(特别是HER2)相关疾病，包括癌症。

Drugs covered by this patent

Patent Metadata

Patent number
CN112266384A
Jurisdiction
CN
Classification
—
Expires
2021-01-26
Drug substance claim
No
Drug product claim
No
Assignee
Dizhe Jiangsu Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.